|
1
|
Scher HI, Solo K, Valant J, Todd MB and
Mehra M: Prevalence of prostate cancer clinical states and
mortality in United States: Estimates using a dynamic progression
model. Plos One. 10:e01394402015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lorente D and De Bono JS: Molecular
alterations and emerging targets in castration resistant prostate
cancer. Eur J Cancer. 50:753–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koivisto P, Kononen J, Palmberg C, Tammela
T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A,
Visakorpi T and Kallioniemi OP: Androgen receptor gene
amplification: A possible molecular mechanism for androgen
deprivation therapy failure in prostate cancer. Cancer Res.
57:314–319. 1997.PubMed/NCBI
|
|
4
|
Tilley WD, Buchanan G, Hickey TE and
Bentel JM: Mutations in the androgen receptor gene are associated
with progression of human prostate cancer to androgen independence.
Clin Cancer Res. 2:277–285. 1996.PubMed/NCBI
|
|
5
|
Gottlieb B, Beitel LK, Wu JH and Trifiro
M: The androgen receptor gene mutations database (ARDB): 2004
update. Hum Mutat. 23:527–533. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chmelar R, Buchanan G, Need EF, Tilley W
and Greenberg NM: Androgen receptor coregulators and their
involvement in the development and progression of prostate cancer.
Int J Cancer. 120:719–733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang G, Wang J and Sadar MD: Crosstalk
between the androgen receptor and beta-catenin in
castrate-resistant prostate cancer. Cancer Res. 68:9918–9927. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heinlein CA and Chang C: Androgen receptor
(AR) coregulators: An overview. Endocr Rev. 23:175–200. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang F, Li X, Sharma M, Sasaki CY, Longo
DL, Lim B and Sun Z: Linking beta-catenin to androgen-signaling
pathway. J Biol Chem. 277:11336–11344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishibashi Y, Matsumoto T, Niwa M, Suzuki
Y, Omura N, Hanyu N, Nakada K, Yanaga K, Yamada K, Ohkawa K, et al:
CD147 and matrix metalloproteinase-2 protein expression as
significant prognostic factors in esophageal squamous cell
carcinoma. Cancer. 101:1994–2000. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Wu G, Yu L, Yuan J, Fang F, Zhai
Z, Wang F and Wang H: Inhibition of CD147 expression reduces tumor
cell invasion in human prostate cancer cell line via RNA
interference. Cancer Biol Ther. 5:608–614. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grass GD, Dai L, Qin Z, Parsons C and
Toole BP: CD147: Regulator of hyaluronan signaling in invasiveness
and chemoresistance. Adv Cancer Res. 123:351–373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szubert S, Szpurek D, Moszynski R, Nowicki
M, Frankowski A, Sajdak S and Michalak S: Extracellular matrix
metalloproteinase inducer (EMMPRIN) expression correlates
positively with active angiogenesis and negatively with basic
fibroblast growth factor expression in epithelial ovarian cancer. J
Cancer Res Clin Oncol. 140:361–369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang F and Wang L, Zhang S, Fang Q, Hao F,
Sun Y, Zhao L, Chen S, Liao H and Wang L: CD147 modulates autophagy
through the PI3K/Akt/mTOR pathway in human prostate cancer PC-3
cells. Oncol Lett. 9:1439–1443. 2015.PubMed/NCBI
|
|
16
|
Sidhu SS, Nawroth R, Retz M,
Lemjabbar-Alaoui H, Dasari V and Basbaum C: EMMPRIN regulates the
canonical Wnt/beta-catenin signaling pathway, a potential role in
accelerating lung tumorigenesis. Oncoqene. 29:4145–4156. 2010.
|
|
17
|
McCubrey JA, Steelman LS, Bertrand FE,
Davis NM, Abrams SL, Montalto G, D'Assore AB, Libra M, Nicoletti F,
Maestro R, et al: Multifaceted roles of GSK-3 and Wnt/β-catenin in
hematopoiesis and leukemogenesis: Opportunities for therapeutic
intervention. Leukemia. 28:15–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scher HI and Sawyers CL: Biology of
progressive, castration-resistant prostate cancer: Directed
therapies targeting the androgen-receptor signaling axis. J Clin
Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verras M and Sun Z: Roles and regulation
of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett.
237:22–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu G, Xu G, Schulman BA, Jeffrey PD,
Harper JW and Pavletich NP: Mol Cell. 11:1445–1456. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu Q, Youn H, Tang J, Tawfik O, Dennis K,
Terranova PF, Du J, Raynal P, Thrasher JB and Li B:
Phosphoinositide 3-OH kinase p85 alpha and p110 beta are essential
for androgen receptor transactivation and tumor progression in
prostate cancers. Oncogene. 27:4569–4579. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takahashi-Yanaga F and Sasaguri T: Drug
development targeting the glycogen synthase kinase-3beta
(GSK-3beta)-mediated signal transduction pathway: Inhibitors of the
Wnt/beta-catenin signaling pathway as novel anticancer drugs. J
Pharmacol Sci. 109:179–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
